FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048893996> ?p ?o ?g. }

• W2048893996 endingPage "1429" @default.
• W2048893996 startingPage "1425" @default.
• W2048893996 abstract "Purpose: Pretreatment prostate-specific antigen velocity (PSAV) greater than 2.0 ng/mL/year has been identified as a predictor of disease-specific survival (DSS) and overall survival (OS) after radiotherapy for prostate adenocarcinoma. This study aimed to independently verify if pretreatment PSAV is associated with biochemical disease-free survival (bDFS), DSS, or OS in men undergoing radiation therapy. Methods and Materials: A total of 473 patients treated with radiation therapy for localized prostate cancer formed the study cohort. No men received neoadjuvant or adjuvant hormones. Kaplan-Meier and Cox regression analysis were used to evaluate if PSAV predicted disease endpoints. Results: Men with a PSAV greater than 2.0 ng/mL/year had a shorter bDFS compared with men with a PSAV of 2.0 ng/mL/year or less (median, bDFS 68 months vs. 97 months; p = 0.0003). However, on multivariate analysis, PSAV was no longer a significant predictor of bDFS in the entire cohort (p = 0.09). PSAV did not predict DSS or OS (p = 0.55 and p = 0.99, respectively). In patients with high-risk disease, PSAV predicted bDFS on univariate (p = 0.0002) and multivariate (p = 0.02) analysis, but not DSS or OS. Conclusion: Pretreatment PSAV greater than 2.0 ng/mL/year is associated with reduced bDFS. However, PSAV is an independent predictor of bDFS only in high-risk patients. PSAV does not predict survival outcomes. Purpose: Pretreatment prostate-specific antigen velocity (PSAV) greater than 2.0 ng/mL/year has been identified as a predictor of disease-specific survival (DSS) and overall survival (OS) after radiotherapy for prostate adenocarcinoma. This study aimed to independently verify if pretreatment PSAV is associated with biochemical disease-free survival (bDFS), DSS, or OS in men undergoing radiation therapy. Methods and Materials: A total of 473 patients treated with radiation therapy for localized prostate cancer formed the study cohort. No men received neoadjuvant or adjuvant hormones. Kaplan-Meier and Cox regression analysis were used to evaluate if PSAV predicted disease endpoints. Results: Men with a PSAV greater than 2.0 ng/mL/year had a shorter bDFS compared with men with a PSAV of 2.0 ng/mL/year or less (median, bDFS 68 months vs. 97 months; p = 0.0003). However, on multivariate analysis, PSAV was no longer a significant predictor of bDFS in the entire cohort (p = 0.09). PSAV did not predict DSS or OS (p = 0.55 and p = 0.99, respectively). In patients with high-risk disease, PSAV predicted bDFS on univariate (p = 0.0002) and multivariate (p = 0.02) analysis, but not DSS or OS. Conclusion: Pretreatment PSAV greater than 2.0 ng/mL/year is associated with reduced bDFS. However, PSAV is an independent predictor of bDFS only in high-risk patients. PSAV does not predict survival outcomes." @default.
• W2048893996 created "2016-06-24" @default.
• W2048893996 creator A5009605712 @default.
• W2048893996 creator A5012511065 @default.
• W2048893996 creator A5035971946 @default.
• W2048893996 creator A5037427247 @default.
• W2048893996 creator A5070464513 @default.
• W2048893996 creator A5090288280 @default.
• W2048893996 date "2007-04-01" @default.
• W2048893996 modified "2023-10-18" @default.
• W2048893996 title "Pretreatment PSA Velocity as a Predictor of Disease Outcome Following Radical Radiation Therapy" @default.
• W2048893996 cites W2034159559 @default.
• W2048893996 cites W2063614609 @default.
• W2048893996 cites W2079357238 @default.
• W2048893996 cites W2090810202 @default.
• W2048893996 cites W2093867637 @default.
• W2048893996 cites W2112689533 @default.
• W2048893996 cites W2116427179 @default.
• W2048893996 cites W2161637485 @default.
• W2048893996 doi "https://doi.org/10.1016/j.ijrobp.2006.11.006" @default.
• W2048893996 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17394943" @default.
• W2048893996 hasPublicationYear "2007" @default.
• W2048893996 type Work @default.
• W2048893996 sameAs 2048893996 @default.
• W2048893996 citedByCount "18" @default.
• W2048893996 countsByYear W20488939962012 @default.
• W2048893996 countsByYear W20488939962013 @default.
• W2048893996 countsByYear W20488939962014 @default.
• W2048893996 countsByYear W20488939962015 @default.
• W2048893996 countsByYear W20488939962016 @default.
• W2048893996 countsByYear W20488939962020 @default.
• W2048893996 countsByYear W20488939962021 @default.
• W2048893996 crossrefType "journal-article" @default.
• W2048893996 hasAuthorship W2048893996A5009605712 @default.
• W2048893996 hasAuthorship W2048893996A5012511065 @default.
• W2048893996 hasAuthorship W2048893996A5035971946 @default.
• W2048893996 hasAuthorship W2048893996A5037427247 @default.
• W2048893996 hasAuthorship W2048893996A5070464513 @default.
• W2048893996 hasAuthorship W2048893996A5090288280 @default.
• W2048893996 hasConcept C105795698 @default.
• W2048893996 hasConcept C121608353 @default.
• W2048893996 hasConcept C126322002 @default.
• W2048893996 hasConcept C126894567 @default.
• W2048893996 hasConcept C143998085 @default.
• W2048893996 hasConcept C144301174 @default.
• W2048893996 hasConcept C161584116 @default.
• W2048893996 hasConcept C2780192828 @default.
• W2048893996 hasConcept C33923547 @default.
• W2048893996 hasConcept C38180746 @default.
• W2048893996 hasConcept C50382708 @default.
• W2048893996 hasConcept C509974204 @default.
• W2048893996 hasConcept C71924100 @default.
• W2048893996 hasConcept C72563966 @default.
• W2048893996 hasConceptScore W2048893996C105795698 @default.
• W2048893996 hasConceptScore W2048893996C121608353 @default.
• W2048893996 hasConceptScore W2048893996C126322002 @default.
• W2048893996 hasConceptScore W2048893996C126894567 @default.
• W2048893996 hasConceptScore W2048893996C143998085 @default.
• W2048893996 hasConceptScore W2048893996C144301174 @default.
• W2048893996 hasConceptScore W2048893996C161584116 @default.
• W2048893996 hasConceptScore W2048893996C2780192828 @default.
• W2048893996 hasConceptScore W2048893996C33923547 @default.
• W2048893996 hasConceptScore W2048893996C38180746 @default.
• W2048893996 hasConceptScore W2048893996C50382708 @default.
• W2048893996 hasConceptScore W2048893996C509974204 @default.
• W2048893996 hasConceptScore W2048893996C71924100 @default.
• W2048893996 hasConceptScore W2048893996C72563966 @default.
• W2048893996 hasIssue "5" @default.
• W2048893996 hasLocation W20488939961 @default.
• W2048893996 hasLocation W20488939962 @default.
• W2048893996 hasOpenAccess W2048893996 @default.
• W2048893996 hasPrimaryLocation W20488939961 @default.
• W2048893996 hasRelatedWork W1570805059 @default.
• W2048893996 hasRelatedWork W1578824628 @default.
• W2048893996 hasRelatedWork W1974427739 @default.
• W2048893996 hasRelatedWork W1978174651 @default.
• W2048893996 hasRelatedWork W1978357124 @default.
• W2048893996 hasRelatedWork W2032728545 @default.
• W2048893996 hasRelatedWork W2036849593 @default.
• W2048893996 hasRelatedWork W2406638334 @default.
• W2048893996 hasRelatedWork W40745829 @default.
• W2048893996 hasRelatedWork W4318262572 @default.
• W2048893996 hasVolume "67" @default.
• W2048893996 isParatext "false" @default.
• W2048893996 isRetracted "false" @default.
• W2048893996 magId "2048893996" @default.
• W2048893996 workType "article" @default.